<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135096</url>
  </required_header>
  <id_info>
    <org_study_id>HMR1964A_3503</org_study_id>
    <nct_id>NCT00135096</nct_id>
  </id_info>
  <brief_title>Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin</brief_title>
  <official_title>APIDRA® (Insulin Glulisine) Administered Premeal vs Postmeal in Adult Subjects With Type 2 Diabetes Mellitus Receiving LANTUS® (Insulin Glargine) as Basal Insulin: a Multicenter, Randomized, Parallel, Open Label Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the change in weight from baseline to study week 52
      in the per-protocol population of pre-meal insulin glulisine (Apidra) versus post-meal
      Apidra, in patients receiving insulin glargine (Lantus) as basal insulin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare change in weight from baseline to study week 52 in the per-protocol population of premeal Apidra vs postmeal Apidra, in patients receiving Lantus as basal insulin</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">345</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glulisine</intervention_name>
    <description>PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes mellitus for at least six months

          -  18 to 70 years of age, inclusive

          -  A1c ≥ 7.5% and ≤ 10%

          -  At least 3 months of continuous insulin and/or insulin analogue therapy (on at least 2
             injections per day) +/- metformin prior to study entry

          -  Negative glutamic acid decarboxylase (GAD) autoantibodies

          -  Ability and willingness to perform self-monitoring of blood glucose (SMBG) at least
             four times a day, and at least 7 times daily during the 7-point blood glucose (BG)
             profile measurement days

          -  Ability and willingness to adhere to, and be compliant with, the study protocol

          -  Must be able to read English or Spanish at the sixth grade level in order to complete
             the patient-reported outcomes component of the study

          -  Signed informed consent

        Exclusion Criteria:

          -  Subjects treated with sulfonylureas, thiazolidinediones (TZDs), or any other oral
             antidiabetic drugs (at study entry) except for insulin and/or insulin analogues with
             or without metformin

          -  Planned pregnancy; or pregnant or lactating females

          -  For subjects treated with metformin: serum creatinine ≥ 1.5 mg/dL (133 µmol/L) for
             males or ≥ 1.4 mg/dL (124 µmol/L) for females

          -  Serum creatinine ≥ 3.0 mg/dL (266 µmol/L)

          -  Any clinically significant renal disease (other than proteinuria) or hepatic disease

          -  Serum ALT or AST levels greater than 2.5 X the upper limit of normal

          -  Any current malignancy or any cancer within the past 5 years (except for adequately
             treated basal cell skin cancer or cervical carcinoma in situ)

          -  Diagnosis of dementia or mental condition rendering the subject unable to understand
             the nature, scope, and possible consequences of the study

          -  Diagnosis of impaired dexterity or vision rendering the subject unable to administer
             multiple daily injections (MDIs)

          -  Cardiac status New York Heart Association (NYHA) III-IV

          -  Hypersensitivity to Lantus or Apidra or any of their components

          -  Any disease or condition (including abuse of illicit drugs, prescription medicines or
             alcohol) that, in the opinion of the investigator or sponsor, may interfere with the
             completion of the study.

          -  Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study

          -  Subject is the investigator or any sub-investigator, research assistant, pharmacist,
             study coordinator, other staff or relative thereof directly involved in the conduct of
             the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Barch, B.S.</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2005</study_first_submitted>
  <study_first_submitted_qc>August 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2005</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

